Anadys Keeps Surging, as Hepatitis C Drug Data Trickles In

2/10/09Follow @xconomy

The more data dribbles out of Anadys Pharmaceuticals, the more investors apparently like what they see. The San Diego-based biotech company said today that one of its experimental drugs for hepatitis C was effective at killing the virus in three more patients who took a low dose in a clinical trial, providing a bit of extra evidence to confirm the results that caused its shares to triple last month.

Anadys CEO Steve Worland provided the update yesterday in a presentation at the BIO CEO investor conference in New York. The company’s stock (NASDAQ: ANDS) climbed 3 percent to $6 at yesterday’s close. It has continued its surge since Jan. 8, when the company said its ANA-598 drug candidate was able to eliminate 99 percent of the virus from the blood, by itself, within 72 hours among the first eight patients in a clinical trial.

The study now shows that ANA-598 is producing about the same amount of viral clearance from the blood with the three additional patients, who got the low dose of 200 milligrams twice a day, Worland says. The company expects to finish enrolling patients in the study by the end of this month, and hopes to present full results at the European Association for the Study of the Liver meeting in Copenhagen, Denmark, in April. The drug is considered important because it is a leader in its class of non-nucleoside polymerase inhibitors, and it ought to be easily combined with some of the 40 new drugs in various stages of clinical or animal testing across the pharmaceutical industry, Worland says. Anadys believes its drug is standing out in the subset of drugs in the non-nucleoside class.

“The non-nucleoside class has been a tough nut to crack,” Worland said in the presentation.

An estimated 170 million people worldwide are infected with hepatitis C virus, a chronic liver bug that can lead to liver failure. A new generation of various virus-killing treatments are promising to change the standard treatment of pegylated interferon and ribavirin, which cures people less than half the time, and causes nasty flu-like side effects that last for almost a year. Cambridge, MA-based Vertex Pharmaceuticals is aiming to blaze a new path with a protease inhibitor drug to improve the cure rate, and shorten treatment. Another class of nucleoside polymerase inhibitors like one from Pharmasset and Roche are working their way through clinical development, ahead of Anadys.

Of course, the Anadys candidate is still very early in clinical trials. The company plans to run another early-stage study this year with healthy volunteers who will take its drug for 14 days, to get more of a sense of how it is absorbed in the body, as well as its safety over a longer period of time, Worland says. Then by mid-2009, the company hopes to start the first mid-stage study of its drug in combination with standard treatments, to see how well it does at improving clinical cure rates after the required 24 weeks. That study should provide an answer in the first half of 2010, Worland said.

But Worland also alluded to the possibility of a partnership in his speech to investors, since big drugmakers are looking to fill gaps in their portfolios with intriguing molecules like the one from Anadys. There is some evidence of Big Pharma interest in the field. Last month, Seattle-based ZymoGenetics signed a partnership with Bristol-Myers Squibb that’s potentially worth as much as $1.1 billion in milestone payments, to develop a modified interferon drug with fewer side effects.

By posting a comment, you agree to our terms and conditions.

  • PEGGY

    how does your program work? WE would like to KNOW more about it. My husband has hep c in the 3rd stage. looking for HELP. THE MEDS HE IS ON NOW IS NOT WORKING FOR HIM. HELP!!

  • PEGGY

    how does a patient become part at your clinic? right now my husband is taking pegylated interferon and ribavirin but his hep c won’t go down, his DR. is going to put on just interferon with ribavirin. anyway we need your help. PLEASE REPLY